DKC1 and cancer: Pyrazofurin (PF) has been tested in clinical trials in colorectal cancer as an orotidine 5′‐monophosphate (OMP) decarboxylase inhibitor, but it was ineffective due to the low response rate and toxicity.[22] Based on our results, precision targeting of tumors with high DKC1 abundance may increase the effectiveness of PF in cancer therapy.